Research progress on the role of lipoxygenase and its inhibitors in prostate cancer.

IF 3 4区医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-11-13 DOI:10.1080/14796694.2024.2419356

Xiaobing Li, Jingxin Mao

引用次数: 0

Abstract

Prostate cancer (PCa) has become a common disease among middle-aged and elderly men. The lipoxygenase (LOX) pathway plays a crucial role in the occurrence, development, invasion and metastasis of PCa and is therefore considered a new target for the prevention and treatment of PCa. 5-LOX and 12-LOX have a promoting effect on the occurrence, development, invasion and metastasis of PCa. 15-LOX-2 has an inhibitory effect on PCa. LOX inhibitors can effectively inhibit the metabolic activity of LOX. The research aims to review the mechanism of action and inhibitors of LOX in PCa, in order to provide relevant references for the prevention and treatment of PCa.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

关于脂氧合酶及其抑制剂在前列腺癌中的作用的研究进展。

前列腺癌（PCa）已成为中老年男性的常见病。脂氧合酶（LOX）通路在 PCa 的发生、发展、侵袭和转移中起着至关重要的作用，因此被认为是预防和治疗 PCa 的新靶点。5-LOX 和 12-LOX 对 PCa 的发生、发展、侵袭和转移有促进作用。15-LOX-2 对 PCa 有抑制作用。LOX 抑制剂能有效抑制 LOX 的代谢活性。本研究旨在综述LOX在PCa中的作用机制和抑制剂，为PCa的预防和治疗提供相关参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.